Drug intelligence / Profile preview

iTOL-200

Development stage
Preclinical
Lead developer
iTOLERANCE
Modality
Cell Therapies, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration
Implantation
01

Overview

iTOL-200 is a 50-micron microgel developed by iTolerance, Inc. It is designed to be co-administered with a liver cell therapy to form iTOL-201. The primary goal of this therapy is to enable ectopic liver implantation without the need for chronic immunosuppression, thereby preventing graft rejection. The microgel is based on the same concept as iTOL-100 and incorporates SA-FasL microgels, suggesting a mechanism aimed at inducing immune tolerance. Early *in vitro* data indicated no significant impact on the survival of hepatocytes when co-administered with SA-FasL microgels. The next developmental step involves evaluating iTOL-201 in preclinical animal models of liver transplantation.

Other names
50 micron microgel

Beyond the preview

Go deeper on iTOL-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on iTOL-200.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call